ArticleTheranostics2026
Cholesterol sulfate replenishment rejuvenates aged hematopoietic stem cell phenomes.
Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aging of hematopoietic stem cells (HSCs) impairs their regenerative and self-renewal capacities, contributing to immune dysfunction and hematologic diseases, yet safe and effective rejuvenation strategies remain elusive. Methods: This study employed a human data-driven, metabolism-centered approach to identify endogenous compounds with rejuvenating potential for aged HSCs. Genome-scale metabolic models and single-cell transcriptomic analyses were used to characterize metabolic changes in human and mouse HSCs. Aged mice were treated with cholesterol sulfate (CS), and HSC functionality was assessed via proliferation assays, DNA damage analysis, and bone marrow transplantation. Molecular docking and Results: Supplementation with CS in aged mice enhanced HSC proliferation, reduced DNA damage, and restored hematopoietic output. Metabolic modeling revealed increased CS hydrolysis as a key alteration in aged HSCs, while single-cell transcriptomics showed that CS treatment suppressed inflammatory signaling and eliminated stress-responsive HSC subpopulations. Mechanistically, CS was identified as a potent ligand that activates RORA. Functional studies suggested that RORA functions as a key mediator in this process. Conclusion: CS supplementation reverses aging-associated HSC decline by enhancing proliferation, reducing DNA damage, and modulating inflammatory pathways, with RORA serving as an essential mediator. These findings highlight the CS-RORA axis as a promising therapeutic target for rejuvenating aged HSCs and preserving hematopoietic function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.